Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Outlook Therapeutics, Inc.NASDAQ: OTLK
EBITDA · Q2 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$14M, compared with -$12.36M a year earlier. Trailing-twelve-month EBITDA was -$62.08M.
Context
- EBITDA amounted to 4497.7% of revenue in FY2025.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of -$10.09M (+84.1%) for the fiscal year ending Sep 2026, a step up from the +11.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$14M-4.0% QoQ
- Last fiscal yearSep 2025
- -$63.58M+11.8% YoY
- LTMMar 2026
- -$62.08M-482.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.2% | +45.6% | +58.8 pp |
| 1 year | +11.8% | +84.1% | +72.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (63.58M) USD
- Year-over-year change
- +11.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (63.58M) | +11.8% |
| FY2024 | 2024-09-30 | (72.09M) | -25.7% |
| FY2023 | 2023-09-30 | (57.38M) | +10.8% |
| FY2022 | 2022-09-30 | (64.36M) | -24.9% |
| FY2021 | 2021-09-30 | (51.51M) | — |
EBITDA vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 EBITDA of -$62.08M is the 8th highest of the 9 companies compared; the peer median is -$22.67M.
- Its year-over-year change of -482.8% is the 8th highest of 9, against a peer median of -4.9%.
- EBITDA amounts to 18634.1% of revenue for OTLK, versus a peer median of 436.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Jun 2026 | -$22.02M | +66.8% | — | 104.8% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| Peer median (excluding OTLK) | -$22.67M | -4.9% | — | 436.9% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K |
| Gross Profit | (262.14K) | (204.69K) | (44.19K) | (113.86K) | 657.21K |
| Gross Margin | — | — | — | — | 46.5% |
| Research & Development | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T |
| Selling, General & Admin | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M |
| Operating Expenses | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| EBITDA | (51.51M) | (64.36M) | (57.38M) | (72.09M) | (63.58M) |
| EBITDA Margin | — | — | — | — | -4497.7% |
| Operating Income | (51.73M) | (63.07M) | (53.13M) | (71.7M) | (67.06M) |
| Operating Margin | — | — | — | — | -4744.3% |
| Interest Income | 0 | 0 | 0 | 906.15K | 89.74K |
| Interest Expense | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K |
| Other Income / Expenses | (1.43M) | (2.98M) | (5.85M) | (3.66M) | 3.08M |
| Income Before Tax | (53.16M) | (66.05M) | (58.98M) | (75.36M) | (63.98M) |
| Pre-Tax Margin | — | — | — | — | -4526.0% |
| Income Tax Expense | 2K | 2.8K | 2.8K | 2.8K | (1.55M) |
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Net Margin | — | — | — | — | -4416.2% |
| EPS (Basic) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| EPS (Diluted) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| Weighted Avg Shares | 7.63M | 10.6M | 12.51M | 18.55M | 34.8M |
| Weighted Avg Shares (Diluted) | 7.63M | 10.6M | 12.51M | 18.55M | 25.48M |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.